招银国际发表报告指，三生制药(01530.HK) 707(PD-1/VEGF)近期公布707(PD-1/VEGF)的II期临床早期数据，展现优效潜力。在单药一线治疗PD-L1+、EGFR/ALK WT NSCLC的试验中，10mg/kg Q3W剂量组有24例患者经历了至少2次肿瘤评估，ORR达到70.8%，高于依沃西单抗(康方生物AK112)在Ib期(HARMONi-5，Link)和III期(HARMONi-2，Link)临床试验中的60%和50%ORR。该行将持续关注后续PFS等数据读出。公司计划在今年启动707治疗NSCLC和CRC的III期临床试验。
招银国际维持对三生制药“买入”评级，目标价由9.81元升至9.91元，指公司估值吸引、盈利增长稳健、创新管线具备出海潜力，预期公司2025年收入和净利润将分别按年增长12%和13%。(ha/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-24 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.